222 related articles for article (PubMed ID: 12086480)
21. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes.
Boer R; Ulrich WR; Klein T; Mirau B; Haas S; Baur I
Mol Pharmacol; 2000 Nov; 58(5):1026-34. PubMed ID: 11040050
[TBL] [Abstract][Full Text] [Related]
22. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase.
Hah JM; Martásek P; Roman LJ; Silverman RB
J Med Chem; 2003 Apr; 46(9):1661-9. PubMed ID: 12699384
[TBL] [Abstract][Full Text] [Related]
23. N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase.
Babu BR; Griffith OW
J Biol Chem; 1998 Apr; 273(15):8882-9. PubMed ID: 9535869
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for isoform-selective inhibition in nitric oxide synthase.
Poulos TL; Li H
Acc Chem Res; 2013 Feb; 46(2):390-8. PubMed ID: 23030042
[TBL] [Abstract][Full Text] [Related]
25. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.
Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841
[TBL] [Abstract][Full Text] [Related]
26. KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization.
Symons KT; Massari ME; Nguyen PM; Lee TT; Roppe J; Bonnefous C; Payne JE; Smith ND; Noble SA; Sablad M; Rozenkrants N; Zhang Y; Rao TS; Shiau AK; Hassig CA
Mol Pharmacol; 2009 Jul; 76(1):153-62. PubMed ID: 19364813
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors.
Prins LH; Petzer JP; Malan SF
Bioorg Med Chem; 2009 Nov; 17(21):7523-30. PubMed ID: 19804982
[TBL] [Abstract][Full Text] [Related]
28. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
29. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
Buolamwini JK; Assefa H
J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
[TBL] [Abstract][Full Text] [Related]
30. The versatile and complex enzymology of nitric oxide synthase.
Gorren AC; Mayer B
Biochemistry (Mosc); 1998 Jul; 63(7):734-43. PubMed ID: 9721327
[TBL] [Abstract][Full Text] [Related]
31. Investigation on Quantitative Structure Activity Relationships of a Series of Inducible Nitric Oxide.
Sharma MC; Sharma S
Interdiscip Sci; 2016 Dec; 8(4):346-351. PubMed ID: 27272764
[TBL] [Abstract][Full Text] [Related]
32. Structure and activity of NO synthase inhibitors specific to the L-arginine binding site.
Proskuryakov SY; Konoplyannikov AG; Skvortsov VG; Mandrugin AA; Fedoseev VM
Biochemistry (Mosc); 2005 Jan; 70(1):8-23. PubMed ID: 15701046
[TBL] [Abstract][Full Text] [Related]
33. Comparative Pharmacophore Modeling and QSAR Studies for Structural Requirements of some Substituted 2-Aminopyridine Derivatives as Inhibitors of Nitric Oxide Synthases.
Sharma MC
Interdiscip Sci; 2015 Jun; 7(2):100-12. PubMed ID: 26202943
[TBL] [Abstract][Full Text] [Related]
34. Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors.
Ji H; Li H; Flinspach M; Poulos TL; Silverman RB
J Med Chem; 2003 Dec; 46(26):5700-11. PubMed ID: 14667223
[TBL] [Abstract][Full Text] [Related]
35. N-Aryl N'-hydroxyguanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases: structure-activity relationship.
Renodon-Cornière A; Dijols S; Perollier C; Lefevre-Groboillot D; Boucher JL; Attias R; Sari MA; Stuehr D; Mansuy D
J Med Chem; 2002 Feb; 45(4):944-54. PubMed ID: 11831907
[TBL] [Abstract][Full Text] [Related]
36. Current trends in QSAR on NO donors and inhibitors of nitric oxide synthase (NOS)*.
Kontogiorgis CA; Hadjipavlou-Litina D
Med Res Rev; 2002 Jul; 22(4):385-418. PubMed ID: 12111751
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases.
Huang H; Martásek P; Roman LJ; Silverman RB
J Med Chem; 2000 Jul; 43(15):2938-45. PubMed ID: 10956202
[TBL] [Abstract][Full Text] [Related]
38. Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis.
Gorren AC; Bec N; Schrammel A; Werner ER; Lange R; Mayer B
Biochemistry; 2000 Sep; 39(38):11763-70. PubMed ID: 10995244
[TBL] [Abstract][Full Text] [Related]
39. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
40. Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.
Sharma H; Cheng X; Buolamwini JK
J Chem Inf Model; 2012 Feb; 52(2):515-44. PubMed ID: 22256860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
